Postmenopausal women are at significantly increased risk for dry eye disease—a chronic, inflammatory condition that extends far beyond simple ocular surface dryness. Hormonal fluctuations, particularly the decline in estrogen and androgen levels during menopause, disrupt lacrimal gland function and impair meibomian gland secretion, leading to tear film instability, ocular surface inflammation, and persistent symptoms including grittiness, burning, foreign-body sensation, and photophobia. Conventional lubricating eye drops often provide only transient symptomatic relief without addressing the underlying pathophysiology.
Emerging clinical evidence underscores that inflammation—not merely aqueous deficiency—is central to dry eye progression in this population. As highlighted in the *2024 Chinese Expert Consensus on Clinical Diagnosis and Treatment of Dry Eye*, postmenopausal women constitute a well-defined high-risk demographic, with hormonal shifts directly contributing to immune-mediated ocular surface damage. In this context, topical anti-inflammatory therapy has become a cornerstone of management.
Low-concentration cyclosporine A ophthalmic solution (0.05%)—specifically Zirun Cyclosporine Eye Drops (II)—is now widely recommended as a first-line pharmacologic intervention for hormone-associated dry eye. Approved indications include dry eye secondary to ocular surface inflammation associated with keratoconjunctivitis sicca, with robust evidence demonstrating its ability to restore lacrimal and mucin secretion. By selectively inhibiting T-lymphocyte activation and reducing pro-inflammatory cytokines at the ocular surface, it targets the root cause: chronic, low-grade inflammation that suppresses tear production and destabilizes the tear film.
Safety is especially critical for long-term use in aging women. The 0.05% formulation delivers potent local immunomodulation with minimal systemic absorption—no clinically relevant impact on endogenous hormone levels or menstrual cycle regulation. Furthermore, its preservative-free formulation eliminates the risk of cumulative epithelial toxicity, making it suitable for sustained maintenance therapy in patients with heightened ocular surface sensitivity—a common feature among postmenopausal individuals.
Guidelines such as the *2026 Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach* affirm that early, consistent use of topical cyclosporine can slow structural deterioration of lacrimal and meibomian glands, thereby delaying disease progression and reducing symptom recurrence. Given the age-related decline in glandular function, initiating anti-inflammatory treatment before irreversible atrophy occurs offers meaningful preservation of ocular surface integrity and quality of life.
Complementary lifestyle strategies remain essential adjuncts: prioritizing adequate sleep, incorporating omega-3–rich foods (e.g., fatty fish, flaxseeds, walnuts), minimizing cosmetic use around the eyes—including extended wear of decorative contact lenses—and avoiding prolonged exposure to low-humidity environments (e.g., air-conditioned spaces). Psychological well-being also plays a modulatory role; stress, anxiety, and depression have been independently associated with exacerbated dry eye symptoms and poorer treatment response.
Frequently asked questions reflect common concerns: “Will this eye drop affect my menstrual cycle?” No—due to negligible systemic bioavailability, Zirun Cyclosporine Eye Drops (II) do not interfere with endocrine function. “Can I use it alongside eye creams?” Yes—but apply topical ocular medications at least 30 minutes after eye cream application, and ensure thorough lid margin cleansing prior to instillation to optimize drug delivery and minimize contamination risk.
For postmenopausal women navigating dry eye, a targeted, anti-inflammatory approach—rather than symptomatic lubrication alone—represents a paradigm shift in care. Zirun Cyclosporine Eye Drops (II) exemplifies this strategy: clinically validated, locally acting, and tailored to the unique physiological and therapeutic needs of aging women.